Home - Prosigna TM - The Prosigna test


Breast cancer: Prosigna test






Following surgery for the removal of breast cancer, the oncologist evaluates the opportunity to submit the patient for chemotherapy. This assessment is normally done on the basis of clinical/pathological factors (lymph node status, tumor size and grade, patient's age, etc.) and immunohistochemical factors (markers of cell proliferation, expression of hormone receptors, etc.).


The Prosigna™ kit provides prognostic indicators and additional information for the oncologist and is useful to identify cases in which chemotherapy can be avoided. Prosigna™ is the only test performed on the national level, which therefore precludes sending samples abroad. It makes use of the analysis of gene expression to identify patients with tumors with low probability of recurrence within 10 years after surgery. In this way, it provides additional information to the clinical/pathological and immunohistochemical factors useful to the physician to identify patients who may avoid chemotherapy following surgery and provide personalized treatment options. The study NEMESI (BMC Cancer, 2012), conducted by Italian researchers, has shown that chemotherapy, along with its side effects, could be avoided in 25% of cases.




 download    Download the brochure



 Anatomic Pathology Unit

 Laboratory of Molecular Diagnostis


 from Monday to Friday, hours 9:00 - 17:00;

 Saturday, hours 9:00 - 14:00





 from Monday to Friday, hours 8:00 - 19:00

 Tel.: (+39) 06.22541.1240







Download this file (UCBM_Prosigna_pazienti_EN.pdf)Prosigna test


Questo sito utilizza i Cookies per migliorare l’esperienza di navigazione e la qualità dei nostri servizi. Continuando la navigazione dichiari di accettare l’utilizzo dei Cookies presenti sul sito. Per saperne di più.